In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer
- PMID: 38085269
- DOI: 10.1158/1078-0432.CCR-23-3087
In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer
Abstract
Chemo-immunotherapy is the current standard of care for extensive-stage small cell lung cancer, but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programmed death ligand-1 expression and tissue tumor mutational burden on durvalumab ± tremelimumab + platinum-etoposide efficacy. See related article by Paz-Ares et al., p. 824.
©2023 American Association for Cancer Research.
Comment on
-
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.Clin Cancer Res. 2024 Feb 16;30(4):824-835. doi: 10.1158/1078-0432.CCR-23-1689. Clin Cancer Res. 2024. PMID: 37801329 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials